Coya Therapeutics

Treg-enhancing biologics, Treg-derived exosomes, Treg cell therapy

modulatingbiologic

coyatherapeutics.com·Houston, Texas, United States·Public

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-IRLR

Summary · Eternal Search editorial

Coya Therapeutics Treg-enhancing biologics, Treg-derived exosomes, Treg cell therapy

Coya Therapeutics is a clinical-stage biotechnology company focused on developing proprietary therapies that enhance regulatory T cell function. Its multi-modality Treg therapies target neurodegenerative, autoimmune, and metabolic diseases. The website cites proof-of-concept data in ALS and Alzheimer's and notes enrollment of the ALSTARS Phase 2 trial for COYA 302 in ALS.

The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →

Plate C·01 · Scientific profile

All 16 dimensions
on the record.

Composite12

Chain scale100 pts

Dimensions16

Plate C·02 · Where it sits among peers

Score vs. proximity
to longevity goals.

Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.

Reading

Coya Therapeutics — Translational · Bottom quartile. Derived deterministically from 5 extracted project(s). Most-advanced status: phase 2. Band: translational. Aging-relevance not LLM-reviewed in this pass.

Source: Deterministic

At a glance

Webcoyatherapeutics.com

HQHouston, Texas, United States

StagePublic

Publications

15 on file

01—The role of regulatory T cells in nervous system pathologies—→02—IL-2-based approaches to Treg enhancement—→03—The Trojan horse – neuroinflammatory impact of T cells in neurodegenerative diseases—→04—Alzheimer’s Disease: From Immune Homeostasis to Neuroinflammatory Condition—→05—Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson’s disease—→06—Regulatory impairment in untreated Parkinson’s disease is not restricted to Tregs: other regulatory populations are also involved—→07—ALS patients’ regulatory T lymphocytes are dysfunctional, and correlate with disease progression rate and severity—→08—Interleukin-2 expands neuroprotective regulatory T cells in Parkinson’s disease—→09—The Characterization of Regulatory T-Cell Profiles in Alzheimer’s Disease and Multiple Sclerosis—→10—Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies—→11—Treg Cells Attenuate Neuroinflammation and Protect Neurons in a Mouse Model of Parkinson’s Disease—→12—The role of regulatory T cells in neurodegenerative diseases—→13—Neuroprotective effects of CD4+CD25+Foxp3+ regulatory T cells in a 3xTg-AD Alzheimer’s disease model—→14—TREGking From Gut to Brain: The Control of Regulatory T Cells Along the Gut-Brain Axis—→15—Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer’s disease—→

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Coya Therapeutics

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

Loading

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.